Should we be concerned about thyroid cancer in patients taking glucagon-like peptide 1 receptor agonists?
Consultant, Narayana Health City, Bangaluru, Karnataka, India.
Subramanian
S
Kannan
Director, Endocrinology Fellowship Program, and Medical Director, Thyroid Center, Cleveland Clinic, Cleveland OH, USA. E-mail: nasrc@ccf.org.
Christian
C
Nasr
D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D000075202:Contraindications; D003921:Diabetes Mellitus, Experimental; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D052216:Glucagon-Like Peptide 1 / Q000819:agonists* / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D008687:Metformin / Q000627:therapeutic use*; D013964:Thyroid Neoplasms / Q000150:complications / Q000175:diagnosis / Q000378:metabolism
D001786:Blood Glucose; D007004:Hypoglycemic Agents; D052216:Glucagon-Like Peptide 1; D008687:Metformin